Drug Trial Radar · NCT02990468
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Mar 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Apr 19, 2017
Primary completion
Feb 21, 2020
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- BioMimetix JV, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Duke University; University of California, San Francisco
- First posted
- Dec 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 / Phase 2 study of newly diagnosed patients with biopsy-proven head and neck cancer (squamous cell carcinoma) who are undergoing standard radiation therapy and treatment with cisplatin. BMX-001 added to radiation therapy and cisplatin is expected to reduce radiation-induced mucositis and xerostomia and also has the potential to benefit the survival of head and neck cancer patients. In Phase 1, safety and tolerability of BMX-001 will be assessed using a Continual Reassessment Method (CRM) and a maximum tolerated dose (MTD) will be determined. BMX-001 will be given subcutaneously first with a loading dose zero to four days prior to the start of chemoradiation and followed by twice a week doses at one-half of the loading dose for the duration of radiation therapy plus two weeks. In Phase 2 both safety and efficacy of BMX-001 will be evaluated. Impact on mucositis and xerostomia will also be assessed. A maximum of 48 patients will be enrolled to the MTD dose determined in Phase 1 to confirm the MTD. The investigators hypothesize that BMX-001 when added to standard radiation therapy and cisplatin will be safe at pharmacologically relevant doses in patients with newly diagnosed head and neck cancer. The investigators also hypothesize that in Phase 2 of this study the addition of BMX-001 will reduce the severity of radiation-induced mucositis and xerostomia in patients receiving head and neck radiation therapy.
Conditions
- Head and Neck Cancer
Interventions
BMX-001Drug
Subcutaneous injection.
Radiation TherapyRadiation
Patients will receive standard dose intensity modulated radiation therapy (IMRT).
CisplatinDrug
Cisplatin will be administered per institution's standard of care practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03.Time frame: 1 year
- Incidence Radiation-induced Mucositis by Clinician ScoringTime frame: 6 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
University of Florida- Gainesville
Gainesville, Florida
University of Nebraska Medical Center
Omaha, Nebraska
Duke University Medical Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.